Lung Cancer Europe shared on LinkedIn:
“This is a really important piece by Talha Jalal – one of Lung Cancer Europe’s Policy Advisors (currently on sabbatical).
He argues that the EU’s medicine strategy is focused on supply chains, but overlooks the deeper risk: drugs becoming ineffective because of underinvestment in trials, antibiotics, and innovation.
For people with lung cancer, it means fewer options and less time.
The Critical Medicines Act won’t fix that on its own.
Published via European University Institute.”
More posts featuring Lung Cancer.